Peptide Knowledge Base · GH-axis

Ipamorelin: what it is, what the evidence says, and its real status

CJC-1295's usual partner, withdrawn on the 503A side and still annotated Category 2 under FDA's 503B interim policy, non-compoundable either way. Education only; the legal GH-axis answer is Sermorelin.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Withdrawn (503A) · Category 2 (503B interim policy).

How does Ipamorelin work?

A selective ghrelin-receptor agonist (GH secretagogue) that prompts pituitary GH release with relatively little effect on cortisol or prolactin.

What it does — and what it does not do

What it does: Studied as a selective GH secretagogue for recovery and sleep interest.

What it does not do: It is non-compoundable in the US and is not offered by Peptós.LIFE, education only.

How honest is the evidence?

Evidence grade C — Mixed / early human evidence.

selective GH secretagogue; human outcome data limited

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Human outcome data is limited; long-term effects are uncharacterized.

WADA status: Banned (S2).

Who should not take it

WADA S2 banned; non-compoundable. Not a substitute for clinical GH evaluation.

Sources

GH-secretagogue clinical literature · FDA compounding Category 2 list (503B interim policy annotation) · FDA bulk drug substances nominated but withdrawn table (content current 04/22/2026)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.